Uncategorized

G1 Therapeutics Announces Upcoming Presentation at the 2023 San Antonio Breast Cancer Symposium

G1 Therapeutics, Inc. announced that an abstract exploring the long-term impact of trilaciclib on survival outcomes in patients with metastatic triple negative breast cancer from the Company’s Phase 2 trial will be presented in a poster session during the upcoming 2023 San Antonio Breast Cancer Symposium, held December 5th through 9th in San Antonio, TX.

G1 Therapeutics Announces Upcoming Presentation at the 2023 San Antonio Breast Cancer Symposium Read More »

Scroll to Top